Carroll David Francis 4
4 · IVERIC bio, Inc. · Filed Apr 25, 2023
Insider Transaction Report
Form 4
IVERIC bio, Inc.ISEE
Carroll David Francis
SVP, CFO and Treasurer
Transactions
- Exercise/Conversion
Common Stock
2023-04-24$1.45/sh+48,171$69,848→ 116,643 total - Exercise/Conversion
Common Stock
2023-04-21$1.45/sh+1,829$2,652→ 70,301 total - Sale
Common Stock
2023-04-21$30.00/sh−1,829$54,870→ 68,472 total - Exercise/Conversion
Stock Option (right to buy)
2023-04-21$1.45/sh−1,829$2,652→ 48,171 totalExercise: $1.45Exp: 2028-12-11→ Common Stock (1,829 underlying) - Sale
Common Stock
2023-04-24$30.21/sh−48,171$1,455,246→ 68,472 total - Exercise/Conversion
Stock Option (right to buy)
2023-04-24$1.45/sh−48,171$69,848→ 0 totalExercise: $1.45Exp: 2028-12-11→ Common Stock (48,171 underlying)
Footnotes (4)
- [F1]The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2022.
- [F2]The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at a price of $30.00 per share on April 21, 2023. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
- [F3]The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $30.00 to $30.51 per share on April 24, 2023. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
- [F4]This stock option award was granted on December 12, 2018 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.